Printer Friendly

STEPHEN DAVIS - NEUROGEN CORPORATION (NRGN).

(LAN621) STEPHEN DAVIS, CEO of NEUROGEN CORPORATION (NRGN), describes the company's business and its background; prospects for the industry, with positive and negative trends; competitive threats; strategic opportunities for the firm including its marketing plans and acquisition potential; management strength and organization; and the financial prospects of the firm looking forward. NEUROGEN CORPORATION (NRGN) is in the industry. Published date 1/15/01. Complete text approximately 3000 words. Document # LAN621.

CEO INTERVIEWS, The Wall Street Transcript, 67 Wall Street, NY 10005. Voice (212) 952 7400. Fax: (212) 668-9842. E-mail: transcript@twst.com.

***
COPYRIGHT 2001 Wall Street Transcript Corporation
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Comment:STEPHEN DAVIS - NEUROGEN CORPORATION (NRGN).
Publication:Wall Street Transcript Digest
Geographic Code:1USA
Date:Jan 15, 2001
Words:92
Previous Article:TONY MORRIS - NEOTONUS INC.
Next Article:GREGORY CASCIARO - ORQUEST INC.
Topics:


Related Articles
Neurogen announces new licensing agreement with Pfizer's Animal Health division
HARRY PENNER JR. - NEUROGEN CORPORATION (NRGN).
CEO INTERVIEW: STEPHEN DAVIS - NEUROGEN CORPORATION (NRGN).
Neurogen and Aventis PHARMA announce worldwide collaboration.
CEO INTERVIEW: WILLIAM KOSTER - NEUROGEN CORPORATION (NRGN).
Neurogen, Merck agreement for pain drugs cleared.
CEO INTERVIEW: WILLIAM KOSTER - NEUROGEN CORPORATION (NRGN).
New genes' discovery confirms immune system may play a role in schizophrenia.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters